News
The decision affects THR-687, a pan RGD integrin antagonist for the treatment ... who do not respond to treatment with blockbuster anti-VEGF drugs like Bayer/Regeneron's Eylea (aflibercept ...
MyChesCo on MSN3mon
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialHe highlighted the drug’s unique mechanism of action, which targets key integrin receptors, and its promise for patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback